EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases
Enteroviruses (EVs) are the most common viral agents in humans. Although most infections are mild or asymptomatic, there is a wide spectrum of clinical manifestations that may be caused by EV infections with varying degrees of severity. Among these viruses, EV-A71 and coxsackievirus (CV) CV-A16 from...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2016-01-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1038/emi.2016.73 |
| _version_ | 1797679198557437952 |
|---|---|
| author | Qunying Mao Yiping Wang Lianlian Bian Miao Xu Zhenglun Liang |
| author_facet | Qunying Mao Yiping Wang Lianlian Bian Miao Xu Zhenglun Liang |
| author_sort | Qunying Mao |
| collection | DOAJ |
| description | Enteroviruses (EVs) are the most common viral agents in humans. Although most infections are mild or asymptomatic, there is a wide spectrum of clinical manifestations that may be caused by EV infections with varying degrees of severity. Among these viruses, EV-A71 and coxsackievirus (CV) CV-A16 from group A EVs attract the most attention because they are responsible for hand, foot and mouth disease (HFMD). Other EV-A viruses such as CV-A6 and CV-A10 were also reported to cause HFMD outbreaks in several countries or regions. Group B EVs such as CV-B3, CV-B5 and echovirus 30 were reported to be the main pathogens responsible for myocarditis and encephalitis epidemics and were also detected in HFMD patients. Vaccines are the best tools to control infectious diseases. In December 2015, China’s Food and Drug Administration approved two inactivated EV-A71 vaccines for preventing severe HFMD.The CV-A16 vaccine and the EV-A71-CV-A16 bivalent vaccine showed substantial efficacy against HFMD in pre-clinical animal models. Previously, research on EV-B group vaccines was mainly focused on CV-B3 vaccine development. Because the HFMD pathogen spectrum has changed, and the threat from EV-B virus-associated severe diseases has gradually increased, it is necessary to develop multivalent HFMD vaccines. This study summarizes the clinical symptoms of diseases caused by EVs, such as HFMD, myocarditis and encephalitis, and the related EV vaccine development progress. In conclusion, developing multivalent EV vaccines should be strongly recommended to prevent HFMD, myocarditis, encephalitis and other severe diseases.Emerging Microbes & Infections (2016) 5, e75; doi:10.1038/emi.2016.73; published online 20 July 2016 |
| first_indexed | 2024-03-11T23:09:54Z |
| format | Article |
| id | doaj.art-f209570f0f3b4dbd896018034cd1f200 |
| institution | Directory Open Access Journal |
| issn | 2222-1751 |
| language | English |
| last_indexed | 2024-03-11T23:09:54Z |
| publishDate | 2016-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj.art-f209570f0f3b4dbd896018034cd1f2002023-09-21T12:27:54ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512016-01-01511710.1038/emi.2016.73EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseasesQunying Mao0Yiping Wang1Lianlian Bian2Miao Xu3Zhenglun Liang4National Institutes for Food and Drug Control, Beijing 100050, ChinaNational Institutes for Food and Drug Control, Beijing 100050, ChinaNational Institutes for Food and Drug Control, Beijing 100050, ChinaNational Institutes for Food and Drug Control, Beijing 100050, ChinaNational Institutes for Food and Drug Control, Beijing 100050, ChinaEnteroviruses (EVs) are the most common viral agents in humans. Although most infections are mild or asymptomatic, there is a wide spectrum of clinical manifestations that may be caused by EV infections with varying degrees of severity. Among these viruses, EV-A71 and coxsackievirus (CV) CV-A16 from group A EVs attract the most attention because they are responsible for hand, foot and mouth disease (HFMD). Other EV-A viruses such as CV-A6 and CV-A10 were also reported to cause HFMD outbreaks in several countries or regions. Group B EVs such as CV-B3, CV-B5 and echovirus 30 were reported to be the main pathogens responsible for myocarditis and encephalitis epidemics and were also detected in HFMD patients. Vaccines are the best tools to control infectious diseases. In December 2015, China’s Food and Drug Administration approved two inactivated EV-A71 vaccines for preventing severe HFMD.The CV-A16 vaccine and the EV-A71-CV-A16 bivalent vaccine showed substantial efficacy against HFMD in pre-clinical animal models. Previously, research on EV-B group vaccines was mainly focused on CV-B3 vaccine development. Because the HFMD pathogen spectrum has changed, and the threat from EV-B virus-associated severe diseases has gradually increased, it is necessary to develop multivalent HFMD vaccines. This study summarizes the clinical symptoms of diseases caused by EVs, such as HFMD, myocarditis and encephalitis, and the related EV vaccine development progress. In conclusion, developing multivalent EV vaccines should be strongly recommended to prevent HFMD, myocarditis, encephalitis and other severe diseases.Emerging Microbes & Infections (2016) 5, e75; doi:10.1038/emi.2016.73; published online 20 July 2016https://www.tandfonline.com/doi/10.1038/emi.2016.73clinical manifestationenterovirus 71 (EV-A71)foot and mouth disease (HFMD)handmultivalent vaccine |
| spellingShingle | Qunying Mao Yiping Wang Lianlian Bian Miao Xu Zhenglun Liang EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases Emerging Microbes and Infections clinical manifestation enterovirus 71 (EV-A71) foot and mouth disease (HFMD) hand multivalent vaccine |
| title | EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases |
| title_full | EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases |
| title_fullStr | EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases |
| title_full_unstemmed | EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases |
| title_short | EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases |
| title_sort | ev a71 vaccine licensure a first step for multivalent enterovirus vaccine to control hfmd and other severe diseases |
| topic | clinical manifestation enterovirus 71 (EV-A71) foot and mouth disease (HFMD) hand multivalent vaccine |
| url | https://www.tandfonline.com/doi/10.1038/emi.2016.73 |
| work_keys_str_mv | AT qunyingmao eva71vaccinelicensureafirststepformultivalententerovirusvaccinetocontrolhfmdandotherseverediseases AT yipingwang eva71vaccinelicensureafirststepformultivalententerovirusvaccinetocontrolhfmdandotherseverediseases AT lianlianbian eva71vaccinelicensureafirststepformultivalententerovirusvaccinetocontrolhfmdandotherseverediseases AT miaoxu eva71vaccinelicensureafirststepformultivalententerovirusvaccinetocontrolhfmdandotherseverediseases AT zhenglunliang eva71vaccinelicensureafirststepformultivalententerovirusvaccinetocontrolhfmdandotherseverediseases |